Home » Stocks » PVCT

Provectus Biopharmaceuticals, Inc. (PVCT)

Stock Price: $0.0695 USD 0.0005 (0.72%)
Updated Jul 21, 2021 3:51 PM EDT - Market closed
Market Cap 27.24M
Revenue (ttm) n/a
Net Income (ttm) -6.52M
Shares Out 402.18M
EPS (ttm) -0.02
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 21
Last Price $0.0695
Previous Close $0.0690
Change ($) 0.0005
Change (%) 0.72%
Day's Open 0.0695
Day's Range 0.0695 - 0.0700
Day's Volume 38,150
52-Week Range 0.0410 - 0.1000

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

KNOXVILLE, TN, July 19, 2021 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from an ongoing clinical trial of investigational cancer immunotherapy PV-10 (rose bengal disodium) for...

5 days ago - GlobeNewsWire

— PV-10 treatment induced autophagic cell death in all breast, colorectal, head and neck, and testicular cancer cell lines tested

1 month ago - GlobeNewsWire

KNOXVILLE, TN, May 25, 2021 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the State of Tennessee, as part of its fiscal year 2021-2022 budget, has directed funding in the amount of $2...

1 month ago - GlobeNewsWire

— Intralesional (aka intratumoral) PV-10 administration for treatment of hepatic metastatic neuroendocrine tumors (NCT02693 0 67)

2 months ago - GlobeNewsWire

KNOXVILLE, TN, March 31, 2021 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that Melanoma Research had published results from an investigator-led, single-center study of Australian in-tran...

3 months ago - GlobeNewsWire

KNOXVILLE, TN, March 30, 2021 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the United States Patent and Trademark Office (USPTO) has allowed US patent (USP) application 16/678,133, w...

3 months ago - GlobeNewsWire

KNOXVILLE, TN, March 23, 2021 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the United States Patent and Trademark Office (USPTO) has allowed US patent application 16/412,872, which c...

4 months ago - GlobeNewsWire

KNOXVILLE, TN, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that H. Lee Moffitt Cancer Center (Moffitt) has released a manuscript preprint describing how investigational aut...

6 months ago - GlobeNewsWire

About PVCT

Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes. It develops PV-10, an investigational autolytic cancer immunotherapy for adult solid tumor cancers, such as melanoma and gastrointestinal tumors, including hepatocellular carcinoma; colorectal cancer metastatic to the liver; neuroendocrine tumors metastatic to the liver; uveal melanoma metastatic to the liver; and pediatric solid tumor cancers, such as neuroblastoma, Ewing sarcoma, rhabdomyosa... [Read more...]

Industry
Biotechnology
Founded
2002
Stock Exchange
OTCMKTS
Ticker Symbol
PVCT
Full Company Profile

Financial Performance

Financial Statements